A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 20 (6) , 489-503
- https://doi.org/10.2165/00002018-199920060-00003
Abstract
Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus. Typically it reduces basal and postprandial hyperglycaemia by...Keywords
This publication has 97 references indexed in Scilit:
- Comparative Tolerability Profiles of Oral Antidiabetic AgentsDrug Safety, 1994
- Metformin Increases Glucose Transporter Protein and Gene Expression in Human FibroblastsBiochemical and Biophysical Research Communications, 1993
- DEMONSTRATION OF DEFECTIVE GLUCOSE UPTAKE AND STORAGE IN ERYTHROCYTES FROM NON-INSULIN DEPENDENT DIABETIC PATIENTS AND EFFECTS OF METFORMINClinical and Experimental Pharmacology and Physiology, 1993
- Treatment with low dose metformin in patients with peripheral vascular diseasePharmacological Research, 1992
- Comparison of Tolbutamide and Metformin in Elderly Diabetic PatientsDiabetic Medicine, 1990
- Oral Hypoglycemic AgentsNew England Journal of Medicine, 1989
- The Effect of Glibenclamide and Metformin on Serum Lipoproteins in Type 2 DiabetesDiabetic Medicine, 1988
- Lactic acidosis in biguanide-treated diabeticsDiabetologia, 1978
- Metformin-induced lactic acidosis in the presence of acute renal failureDiabetologia, 1977
- Malabsorption of Vitamin B12 in Diabetic Patients Treated with Phenformin: A Comparison with MetforminBMJ, 1973